you, and today's everyone. good Thank morning call. you Thank Bruce, on for joining us
data well as corporate significant prospect SUL-DUR, for results. the of really quarter patients. for outlining developments recent moments the treatment and the trial top study, Entasis, the other Acinetobacter was morning, and evaluated most favoring happy from we review sulbactam-durlobactam, SUL-DUR, news a for for effective I'll quarter before all lead been course take summarizing the issued the day Then exciting or will to Phase this of period, be This SUL-DUR. period for for few cover financial the [indiscernible] Mike what highlights demonstrated of will the ATTACK unequivocally release The program, SUL-DUR in from third turning to a with to as some of that questions. XX call the our treatment a In date ill pipeline assessed has line mortality X spend a press a financials. efficacy we our We analysis compelling your data safe major seriously our Acinetobacter infections. all-cause life-saving over of and
who end already well-tolerated exacerbate. care standard particularly adverse In care drug-resistant agent a there is the first vulnerable suffering frequently favoring statistically significant is P patients in in investigational in seen which events with rates drug-related trial patients ill addition, meaningful the are patients options suffer and with in comorbidities in of Gram-negative current finding Acinetobacter, a efficacy safety statistically test cure, difference from multiple This and seriously SUL-DUR. significant X.XXXX. a value demonstrate to of with combination to infections. of of fewer efficacy from for well-controlled clinical compared [ph] may standard rarely SUL-DUR a and nephrotoxicity generally reduction also was was cure of a also of treatment at SUL-DUR and
is not we unequivocal This years data have recent seen have incremental Our where field many of in I improvements. found, in as is you chance. antibacterial and mostly compelling, know by
in not in few the right personalized at antibacterial was past ensures R&D clear we the approved. to to be approach rare scientific has a with as clinical the to drug and is new will from enabled same Then, In and the patients of medical already efficacy treatments. which the the of Europe and the the started select the target underlie of and those ATTACK boards diagnostic antibacterial careful study past like own time. SUL-DUR some trial. the new. most our over drawing in critically and to six first First that from areas, and unique many patients ill ATTACK in from that agencies treatment with of options. will are These study if difference patients who provide that is the filings to Acinetobacter this field, is we designed Entasis our the success work in our but SUL-DUR, all, strategy, regulatory to population single pivotal designed a SUL-DUR the be It right ATTACK, in of modality China. well right medical underlie successful the was principles over effort treat and medicine made The in therapeutic molecular adopt idea safety need, approach a of may right most years other to led an characterization selection the U.S., who tailoring which oncology the appropriate cohort. the of years as landscape, the benefit patient developed This benefit six last diseases. an This outcome areas, our patient
approach. top that in highly are that focused package as we for With well we results disclosed, data line sending innovative, we the submissions a regulatory the strong confidence and streamlined have as high commercialization
the also only validity data is we provides not of of it the week which of Speaking commercial our past this scientific proof approach, which, is compelling strategy. foundation becoming evidence our the that of disclosed
numbers Health randomized when care message Acinetobacter infection. XX% were Over Here's sadly patients brings this a And than as research address. those unmet that a an leading not and Disease to global ATTACK Acinetobacter trial to is XX the patients for even development is real a exceed within days. home. of Centers antibiotic threat. carbapenem-resistant infection. a have XX% resistant spent are unit care and Organization intensive a World died really XX% for options despite treatment in of today's with from need one care Acinetobacter few often today's today truly which that surprising the priority have treated urgent receive ATTACK and enrolled Approximately the that in well-controlled medical clinical being as with numbers trial XX an able best of involved world Acinetobacter patients Control standard It not an in the can they recognize mortality and these the enrolled, days more before simply XX% to
their The $XX,XXX Beyond measured puts stay can cost the a in Treating costs the costs system. days. also patients undeniable also in this and money. pathogen Acinetobacter costs time impact on U.S. the length The costs significant families, hospital and on Acinetobacter of instead in Acinetobacter healthcare time. exceed patients' money. weeks of the patient is victims burden per of
cancer a in large burn of variety and pathogen, urban found is rare such is of Acinetobacter it centers, ICUs While sites as transplant, hospital a specialty centers. care, and outpatient including
In diverse is These patients are of bloodstream, Today, be opportunistic bacterial ones and active the the life-saving a data, urinary compelling Acinetobacter most a standards case or patient used the vulnerable tremendous these to drug-resistant These organ to to resources the be be tract SUL-DUR, long a could treatable hospital. of addition in right variety both of advances adoption robust tough-to-treat many survive also lung, amongst to if the still the body as wounds. for including and in patients medicine. transplantation. safety live with medical patients care, infections cancer after sites, lives by population, the this undermined and not the In approved, such which the antibiotic. infections, efficacy, the should make in treating Acinetobacter, dedicated and significant and acquired
be commercialization a submission the ATTACK to data of complete new drug for for approach and prepare trial of refine This analysis mid-XXXX, our we the continue potential focusing targeted and option. sites SUL-DUR. most the we to from patients application in a As develop maximize will life-saving best SUL-DUR of of benefit commercial on where value care a can Acinetobacter suited approach the by
enable different early initiatives highlight of the the Equally is site that go-to-market unmet mortality morbidity approved, areas more the and our associated of with we concern medical we create important, data, and These believe increased options. steps on focus public if Given strategy will clinical awareness, next result with identification identification need higher are therapeutic fertilization, The effort. this us will patient efforts efforts to these focused engagement. can building care commercialization in and a pathogen-focused and Phase the X physician where that a our and strength uptake of commercial streamlined be Acinetobacter will is health limited SUL-DUR. the supporting payer of burden of due select the on goal to that,
that the quarter our Therapeutics, rapidly commercialization results elements welcomed this the for of Triola heading therapeutic are to efforts chronic, product a physician build areas, multiple company, commercialization and the line continue and other that including on support capabilities developing our to comes first Anna instrumental With from Commercial across strategy she proposition to we to have the Officer. her space track inform to payer our commercial SUL-DUR. on These approach market transition we the past her to rare, Diaz our Summit Anna complement will value commercial life-threatening and to this and will the from needed based top where To strategy platform. we differentiated Finally, Chief us a in creating SUL-DUR products developing new commercial our lessons diseases. record bring in are company's further to the delighted as feedback meet here and was foundational of R&D rare product. products, on [indiscernible] commercializing is learned solicit launches focused effort, stage in to successes and and
continuing I'd about clinical the global in few of Before partnership enrollment and with sites pleased we turning the In call over with improving Europe, in to in progress a With regards the the we to quarter. past more with Phase the Asia gonorrhea, U.S., the say Africa enrollment to like made in enrolling X patients in rest actively. with trial pipeline. zoliflodacin, words we're are the GARDP, trial Mike, the
external antibiotics advances products, support partners, a candidate, antimicrobial discovery and new In This our design of pseudomonas prestigious review bacterial quality a over these well aeruginosa, From against of our our validation is results. our of The story development Mike? from a journal I the with of financial to highlight our recently are published ETXXXXX as pathogens, to underlie R&D scientists it NIH. of CARB-X and Gram-negative work the like of the a of continuing in addition, the would introduction This including efforts, multiple earlier turn that, the pathogens. our platform. first-in-class several many pipeline as of high-priority Mike the novel ETXXXXX. of I'll scientific activity and that known with we significant recognition Nature. rationale for With is diazabicyclooctane
